Business
Starbucks American Coffee Chain Cafe In Amsterdam
(Nicolas Economou/Getty Images)
Opinion

Starbucks could use a CIO

Customers give Starbucks billions of dollars in prepaid credits each year. Should the coffee chain be investing it?

Jack Raines

Every six months someone resurfaces the internet’s favorite business coffee story: Is Starbucks really a bank? (My favorite edition of this question is Trung Phan’s X thread from 2022.) The TL;DR is that Starbucks runs a first-class rewards program that incentivizes customers to preload their Starbucks accounts with cash in exchange for stars that can be redeemed for free food, drinks, and merch. Customers earn 2 Stars per $1 spent with loaded funds on their app, versus 1 Star per dollar spent with cash, credit, or debit cards through their app.

This money stored in customers’ accounts appears as a liability on Starbucks’ balance sheet as “stored value cards and loyalty program” within deferred revenue.

Starbucks 10Q

Stored value capital is essentially an interest-free loan from the customer to the business that can only be exchanged for coffee (and other Starbucks products), and it can’t be redeemed for cash.

This program has been a hit, and, according to Starbucks’ most recent 10-Q, they currently have $2.2 billion (!!) in stored value cash on their balance sheet. As if this weren’t a good enough deal for Starbucks, a portion of this stored value goes unspent each year, which Starbucks recognizes as “breakage revenue.”

The success of Starbucks’ Rewards program poses an interesting question: why doesn’t the coffee chain launch an investing arm to manage these funds?

This model of investing excess capital has existed for years in the insurance industry. Insurance companies invest their float, which is the difference between premiums paid by customers and claims paid to customers, across different assets to increase their returns. Most insurers invest in low-risk bonds with durations that match their liabilities (auto insurers invest in shorter duration bonds, life insurers invest in longer duration bonds), but insurers don’t have to limit their investments to the bond market.

Take Berkshire Hathaway: in Berkshire’s 2009 annual shareholder letter, Warren Buffett noted that their float had grown from $16 million in 1967 to $62 billion in 2009, giving them billions of interest-free money to invest, which Berkshire has actively deployed in public markets.

Starbucks’ reward system has created a “float” with a guaranteed profit in the form of “breakage revenue.” Unlike insurers, who need to account for the risk that claims could outpace premiums collected in a given year, Starbucks’ Rewards outflows will never cost more than their inflows because money stored in their rewards program can only be redeemed for Starbucks’ products. Put simply, the coffee chain will never owe more than it has received from customers. Even better, Starbucks accurately forecasts how much money won’t be redeemed through its breakage revenue, meaning that the company knows how much of its stored value is pure profit.

So why not invest that $2 billion, or at least its estimated breakage revenue each year, and compound it over time?

More Business

See all Business
business

Hims to stop offering copy of Wegovy pill following FDA scrutiny

Hims & Hers said it has decided to stop offering its newly launched copycat version of Novo Nordisk’s Wegovy pill, after the telehealth company drew criticism from the Food and Drug Administration. 

“Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment,” Hims wrote on X.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Hims oral semaglutide

Hims, long flying under regulators’ radar, finally strikes a nerve with its Wegovy pill copy

It’s unclear if the pill Hims is selling works or if the FDA will allow it.

$1.3M

There’s still plenty of money to be made in brainrot. The top 1,000 Roblox creators earned an average of $1.3 million in 2025 — up 50% from the year prior — according to CEO Dave Baszucki on the company’s fourth-quarter earnings call.

Roblox paid out $1.5 billion to creators last year, meaning its top 1,000 creators took home about 87% of the total pool.

Like other creator economy giants, Roblox rewards its biggest creators for their contributions to user engagement. Creator-made titles like “Grow a Garden” and “Steal a Brainrot” substantially boosted playing time over the course of the year. In September, the company increased its developer exchange rate, or the ratio of in-game currency to cash payout, by 8.5%.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.